Comparative Pharmacology
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 versus DOBUTREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5 versus DOBUTREX.
DOBUTAMINE HYDROCHLORIDE IN DEXTROSE 5% vs DOBUTREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dobutamine is a direct-acting inotropic agent primarily stimulating β1-adrenergic receptors, with mild β2 and α1 activity, increasing cardiac contractility and stroke volume.
Dobutamine is a direct-acting inotropic agent primarily stimulating beta-1 adrenergic receptors, with mild beta-2 and alpha-1 effects. It increases myocardial contractility and stroke volume, resulting in increased cardiac output.
IV continuous infusion: 2.5-20 mcg/kg/min titrated to hemodynamic response; start at 2.5-5 mcg/kg/min. Max dose: 40 mcg/kg/min.
2.5-20 mcg/kg/min continuous IV infusion; titrate to hemodynamic response.
None Documented
None Documented
Terminal elimination half-life is approximately 2 minutes. Short half-life necessitates continuous intravenous infusion for sustained hemodynamic effect.
Terminal elimination half-life approximately 2 minutes; clinical effects wane within minutes of infusion cessation due to rapid redistribution and metabolism
Primarily renal (urinary) elimination; majority as metabolites (3-O-methyldobutamine and conjugates). Less than 5% excreted unchanged in urine. Minor biliary/fecal excretion.
Renal: 75-80% as metabolites (3-O-methyl-dobutamine and conjugates) and unchanged drug; minor biliary/fecal elimination (<5%)
Category C
Category C
Inotropic Agent
Inotropic Agent